High costs associated with specialty pharmacy will necessitate the evolution of a new specialized model to help ensure that patients are receiving the financial assistance they need and adhering to their treatment, according to Steve Miller, MD, senior vice president and chief medical officer of Express Scripts.
High costs associated with specialty pharmacy will necessitate the evolution of a new specialized model to help ensure that patients are receiving the financial assistance they need and adhering to their treatment, according to Steve Miller, MD, senior vice president and chief medical officer of Express Scripts.
Transcript (slightly modified)
What is specialty pharmacy’s role in new care delivery models like accountable care organizations and patient-centered medical homes?
So when you’re talking about various patients’ very expensive therapies you’re actually going to need to deliver care in a much better way than we have historically. You don’t want to be wasting a single dollar so you don’t want a single patient not adhering. And so we’re really going to have to have a specialized model where we have specialized pharmacists and nurses and social workers dealing with each and every patient to make sure they actually get the patient the financial assistance they need, get the medical care they need, get the coordination of care they need. And so this is going to challenge the system where we’re going to have to evolve to a whole different model than what we have today.
In regards to indication-based pricing in oncology, what are the outcomes that are being considered? Is it overall survival alone or are surrogates, like duration of response rate, also being used?
With our indication-based pricing it’s starting in a small experiment because we have to actually get it right. That is, right now we need the integrity of the data so that we can report out to both the plan sponsors and the patients but also the pharmaceutical manufacturers about who’s being treated, what they’re being treated for. It’s a totally different way of processing claims. In the near future we’re actually going to be expanding it to where we’re looking at outcomes, and those outcomes are both financial outcomes but also clinical outcomes because we want to make sure that patients continue to get the very best care possible but also get savings where possible.
Dr Dalia Rotstein: Physicians Must Be Aware MS Affects People of All Backgrounds
April 24th 2024Dalia Rotstein, MD, MPH, emphazises the importance of awareness that multiple sclerosis (MS) impacts patients from various backgrounds as clinicians think through ways to improve access to care and research efforts in MS.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Beyond Insulin: The Impact of Next-Generation Diabetes Technology
April 17th 2024Experts explain how new diabetes technologies like continuous glucose monitors are transforming care beyond intensive insulin therapy, offering personalized insights and improving outcomes for patients of all treatment levels.
Read More
Empowering Community Health Through Wellness and Faith
April 23rd 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In the third episode, Camille Clarke-Smith, EdD, MS, CHES, CPT, discusses approaching community health holistically through spiritual and community engagement.
Listen
Dr Michael Farwell on FDG PET/CT Imaging to Predict Immunotherapy Response in Advanced Melanoma
April 15th 2024Michael Farwell, MD, associate professor of radiology at the Hospital of the University of Pennsylvania, provides insights into a study on the benefits of using 18F-fluorodeoxyglucose (FDG) PET/CT imaging to detect metabolic tumor changes in skin cancer.
Read More